#COVID-19 vaccine

The update aims to help the public better protect themselves and understand their risk.

Antibody levels decrease substantially within three months after a booster, according to new clinical trial data.

The engineered protein vaccine was highly effective in a clinical trial but faced a long delay for authorization.

After a long wait, the FDA authorizes Pfizer and Moderna vaccines for children as young as 6 months old.

Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.

Approximately 1 in 3 Americans 65 and older who completed their initial vaccination round still have not received a first booster shot.

The United States might see one of the steepest increases in the country’s uninsured rate in years.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.

While vaccination typically provides robust protection against severe disease, they’re less effective for immunocompromised people.

Novel therapies, improved technologies and a better understanding of the immune system could yield broad dividends.

Immunocompromised people ages 12 and older are also eligible for an additional shot.

Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.

Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.

Transplant recipients, people with advanced HIV and certain people with cancer or autoimmune diseases can get an additional vaccine dose.

Boosters reduced the risk of hospitalization and death by about 80% for people with HIV, cancer, autoimmune conditions or organ transplants.